These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 28633409)

  • 21. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
    Das M; Ogale S; Jovanoski N; Johnson A; Nguyen C; Bhagwakar J; Lee JS
    Immunotherapy; 2023 Jun; 15(8):573-581. PubMed ID: 37021770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non-Small Cell Lung Cancer in the Irish Healthcare Setting.
    Chu RW; Vegas García A; Hickey C; Power DG; Gorry C
    Value Health; 2023 Mar; 26(3):402-410. PubMed ID: 36368626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Bravaccini S
    Lung Cancer; 2019 Jun; 132():152-153. PubMed ID: 30879776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
    Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.
    Leung JH; Chang CW; Chan AL; Lang HC
    Future Oncol; 2022 Mar; 18(7):859-870. PubMed ID: 35105168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.
    Wu C; Li W; Tao H; Zhang X; Xin Y; Song R; Wang K; Zuo L; Cai Y; Wu H; Hui W
    Crit Rev Oncol Hematol; 2024 Jan; 193():104195. PubMed ID: 37931769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study.
    Plessala I; Cawston H; Cortes J; Ajjouri R; Le Lay K; Souquet PJ; Chouaid C
    Lung Cancer; 2023 Oct; 184():107316. PubMed ID: 37562344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
    Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
    J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
    Chisaki Y; Nakano H; Minamide J; Yano Y
    Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 38. PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
    Dong A; Zhao Y; Li Z; Hu H
    J Gene Med; 2021 Feb; 23(2):e3294. PubMed ID: 33171529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
    Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
    Adv Ther; 2021 May; 38(5):2447-2457. PubMed ID: 33821431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA.
    Huang M; Lopes GL; Insinga RP; Burke T; Ejzykowicz F; Zhang Y; Feliciano JL
    Immunotherapy; 2019 Dec; 11(17):1463-1478. PubMed ID: 31738117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.